Novo’s Wegovy (NOVOB DC) reduced liver fat to normal levels in 9 out of 10 adults with obesity and excess liver fat

For the GLP-1 franchise, indications beyond weight loss have been the established route to defending pricing and broadening reimbursement, and liver disease has been one of the most actively contested of those adjacencies, with the same mechanism being run across metabolic liver conditions by both the incumbent pair and a field of smaller challengers. Headline efficacy percentages from a sponsor release tend to land softly without the comparator arm, the trial design, and the endpoint hierarchy; in past episodes of this kind, the durable moves have come from whether the data support a formal label expansion and payer coverage rather than from the topline claim alone. The case distinction that matters is between data in a population selected for excess liver fat and the harder endpoints, such as fibrosis resolution or outcomes in advanced disease, which regulators and payers have historically weighted more heavily. Worth noting is the competitive read-across: liver data from one franchise has tended to reprice the peer set developing rival mechanisms in the same indication. Follow-ons are the full dataset, any regulatory filing intent, and the competitor readout calendar in the same space.